Table 2.
Comparison of transaminases levels at baseline and 3-month follow-up in treatment and control groups.
| Groups (n = 230) | Baseline (IU/L) | 3 month follow-up | p value∗ | |
|---|---|---|---|---|
| Treatment group (n = 106) | SGPT (IU/L) | 73.1 ± 20.4 | 44.6 ± 34.2 | <0.001 |
| SGOT (IU/L) | 60.2 ± 24.5 | 38.3 ± 20.8 | <0.001 | |
|
| ||||
| Control group (n = 124) | SGPT (IU/L) | 63.4 ± 15.1 | 55.8 ± 45.9 | 0.161 |
| SGOT (IU/L) | 46.8 ± 13.7 | 45.5 ± 30.9 | 0.728 | |
∗Paired t-test. SGPT: serum glutamic pyruvic transaminase; SGOT: serum glutamic-oxaloacetic transaminase.